<Version><xmlsource>This XML content was developed by AHRQ's contractor ECRI Institute for the National Guideline Clearinghouse (NGC).</xmlsource><Section SecID="390" OrdBy="100" Name="General"><Field FieldID="161" OrdBy="105" ID="391" Name="Guideline Title" Type="text"><FieldValue Value="&lt;div class=&quot;content_title&quot;&gt;Rheumatoid arthritis: diagnosis, management and monitoring.&lt;/div&gt;" /></Field><Field FieldID="97" OrdBy="110" ID="392" Name="Bibliographic Source(s)" Type="citation"><FieldValue Value="&lt;table&gt;&lt;tr&gt;&lt;td&gt;Medical Services Commission. Rheumatoid arthritis: diagnosis, management and monitoring. Victoria (BC): British Columbia Medical Services Commission; 2012 Sep 30. 7 p.  [12 references]&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;" /></Field><Field FieldID="120" OrdBy="115" ID="393" Name="Guideline Status" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;This is the current release of the guideline.&lt;/p&gt;&lt;/div&gt;" /></Field><Field Name ="UMLS Concepts"><FieldValue Value="ICD9CM: Arthrocentesis  (81.91); Rheumatoid arthritis  (714.0); Screening for rheumatoid arthritis  (V82.1)"/><FieldValue Value="MSH: Acetaminophen ; Anti-Inflammatory Agents, Non-Steroidal ; Antibodies, Antinuclear ; Antirheumatic Agents ; Arthritis, Rheumatoid ; Blood Sedimentation ; C-Reactive Protein ; Comorbidity ; Diagnosis, Differential ; Diagnostic Imaging ; Disease Management ; Hydroxychloroquine ; Medication Therapy Management ; Methotrexate ; Patient Education as Topic ; Prednisone ; Referral and Consultation ; Sulfasalazine "/><FieldValue Value="MTH: Acetaminophen ; Anti-Inflammatory Agents, Non-Steroidal ; Antibodies, Antinuclear ; Antirheumatic Agents ; Arthrocentesis ; Blood Sedimentation ; C-reactive protein ; C-reactive protein measurement ; Diagnostic Imaging ; Differential Diagnosis ; Disease Management ; Encounter due to screening for rheumatoid arthritis ; Erythrocyte sedimentation rate measurement ; follow-up ; Methotrexate ; Patient education (procedure) ; Patient Monitoring ; Prednisone ; Rheumatoid Arthritis ; Rheumatoid Factor Measurement "/><FieldValue Value="PDQ: acetaminophen ; diagnostic imaging ; hydroxychloroquine ; methotrexate ; prednisone "/><FieldValue Value="SNOMEDCT_US: Acetaminophen  (387517004); Acetaminophen  (90332006); Anti-rheumatic agent  (372888006); Anti-rheumatic agent  (88279005); Antinuclear antibody  (45530001); Arthrocentesis  (179906007); Arthrocentesis  (90131007); C reactive protein  (61425002); C-reactive protein measurement  (55235003); Diagnostic aspiration of joint  (274391001); Differential diagnosis  (47965005); Disease modifying antirheumatic drug monitoring  (401192009); Erythrocyte sedimentation  (416560009); Erythrocyte sedimentation rate measurement  (416838001); Examination of joint  (284393006); Hydroxychloroquine  (373540008); Hydroxychloroquine  (83490000); Imaging  (363679005); Methotrexate  (387381009); Methotrexate  (68887009); Monitoring of patient  (182777000); Non-steroidal anti-inflammatory agent  (16403005); Non-steroidal anti-inflammatory agent  (372665008); Patient education  (311401005); Prednisone  (10312003); Prednisone  (116602009); Rheumatoid arthritis  (69896004); Rheumatoid factor measurement  (54921001); Rheumatoid factor screening test  (394976001); Sulfasalazine  (387248006); Sulfasalazine  (45844004)"/><FieldValue Value="UMD: Analyzers, Laboratory, Hematology, Erythrocyte Sedimentation Rate  (15-177); Radiographic Systems  (18-429)"/></Field></Section><Section SecID="394" OrdBy="200" Name="Regulatory Alert"><Field FieldID="154" OrdBy="205" ID="395" Name="FDA Warning/Regulatory Alert" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;&lt;strong&gt;Note from the National Guideline Clearinghouse&lt;/strong&gt;: This guideline references a drug(s) for which important revised regulatory and/or warning information has been released.&lt;/p&gt;&#xD;&#xA;&lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;    &lt;li&gt;&lt;a href=&quot;http://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm454141.htm&quot; title=&quot;FDA Web site&quot; target=&quot;_blank&quot;&gt;July 9, 2015 - Non-aspirin Nonsteroidal Anti-inflammatory Drugs (NSAIDS)&lt;/a&gt;: The U.S. Food and Drug Administration (FDA) is strengthening an existing label warning that non-aspirin nonsteroidal anti-inflammatory drugs (NSAIDs) increase the chance of a heart attack or stroke. Based on FDA&amp;rsquo;s comprehensive review of new safety information, FDA is requiring updates to the drug labels of all prescription NSAIDs. As is the case with current prescription NSAID labels, the Drug Facts labels of over-the-counter (OTC) non-aspirin NSAIDs already contain information on heart attack and stroke risk. FDA will also request updates to the OTC non-aspirin NSAID Drug Facts labels. &lt;/li&gt;&#xD;&#xA;&lt;/ul&gt;&lt;/div&gt;" /></Field></Section><Section SecID="396" OrdBy="300" Name="Scope"><Field FieldID="140" OrdBy="305" ID="397" Name="Disease/Condition(s)" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;Rheumatoid arthritis (RA)&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="103" OrdBy="310" ID="398" Name="Guideline Category" Type="picklist-many"><FieldValue Value="Diagnosis" /><FieldValue Value="Evaluation" /><FieldValue Value="Management" /><FieldValue Value="Treatment" /></Field><Field FieldID="113" OrdBy="315" ID="399" Name="Clinical Specialty" Type="picklist-many"><FieldValue Value="Family Practice" /><FieldValue Value="Internal Medicine" /><FieldValue Value="Rheumatology" /></Field><Field FieldID="114" OrdBy="320" ID="400" Name="Intended Users" Type="picklist-many"><FieldValue Value="Occupational Therapists" /><FieldValue Value="Physical Therapists" /><FieldValue Value="Physician Assistants" /><FieldValue Value="Physicians" /></Field><Field FieldID="129" OrdBy="325" ID="401" Name="Guideline Objective(s)" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;To aid in early recognition, intervention and management of patients with rheumatoid arthritis (RA)&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="132" OrdBy="330" ID="402" Name="Target Population" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;Patients 16 years of age and older with early or established rheumatoid arthritis (RA)&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="133" OrdBy="335" ID="403" Name="Interventions and Practices Considered" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;&lt;strong&gt;Diagnosis&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;ol style=&quot;list-style-type: decimal;&quot; start=&quot;1&quot;&gt;&#xD;&#xA;    &lt;li&gt;Differentiation of inflammatory from non-inflammatory arthritis &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Differentiation of rheumatoid arthritis (RA) from other inflammatory arthritis &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Lab and imaging tests (along with clinical features)&#xD;&#xA;    &lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;        &lt;li&gt;C-reactive protein (CRP) or erythrocyte sedimentation rate (ESR) &lt;/li&gt;&#xD;&#xA;        &lt;li&gt;Rheumatoid factor latex test (RF) &lt;/li&gt;&#xD;&#xA;        &lt;li&gt;Antinuclear antibody (ANA) &lt;/li&gt;&#xD;&#xA;        &lt;li&gt;X-rays &lt;/li&gt;&#xD;&#xA;        &lt;li&gt;Joint aspiration &lt;/li&gt;&#xD;&#xA;    &lt;/ul&gt;&#xD;&#xA;    &lt;/li&gt;&#xD;&#xA;&lt;/ol&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Management/Treatment&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;ol style=&quot;list-style-type: decimal;&quot; start=&quot;1&quot;&gt;&#xD;&#xA;    &lt;li&gt;Referral to specialists &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Patient education &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Nonsteroidal anti-inflammatory drugs (NSAIDs) and acetaminophen for pain &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Hydroxychloroquine until diagnosis of RA &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Sulfasalazine and methotrexate if confident about RA diagnosis &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Low-dose prednisone &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Monthly visits to monitor response &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Long-term disease-modifying anti-rheumatic drug (DMARD) therapy &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Follow-up&#xD;&#xA;    &lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;        &lt;li&gt;Assess drug therapy &lt;/li&gt;&#xD;&#xA;        &lt;li&gt;Examine joints &lt;/li&gt;&#xD;&#xA;        &lt;li&gt;Serial assessment if CRP or ESR is elevated &lt;/li&gt;&#xD;&#xA;        &lt;li&gt;Review general health concerns and co-morbidities &lt;/li&gt;&#xD;&#xA;    &lt;/ul&gt;&#xD;&#xA;    &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Consideration of implications of chronic disease &lt;/li&gt;&#xD;&#xA;&lt;/ol&gt;&lt;/div&gt;" /></Field><Field FieldID="134" OrdBy="340" ID="404" Name="Major Outcomes Considered" Type="text"><FieldValue Value="&lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;    &lt;li&gt;Quality of life &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Life expectancy &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Permanent joint damage &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Cardiovascular risk &lt;/li&gt;&#xD;&#xA;&lt;/ul&gt;" /></Field></Section><Section SecID="405" OrdBy="400" Name="Methodology"><Field FieldID="109" OrdBy="405" ID="406" Name="Methods Used to Collect/Select the Evidence" Type="picklist-many"><FieldValue Value="Searches of Electronic Databases" /></Field><Field FieldID="135" OrdBy="410" ID="407" Name="Description of Methods Used to Collect/Select the Evidence" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;Evidence was obtained through a systematic review of peer-reviewed literature (up to June 2012) using the databases MEDLINE, PubMed, EBSCO, Ovid, and the Cochrane Collaboration's Database for Systematic Reviews. Search terms: rheumatoid arthritis, differential diagnosis, treatments, biologics, DMARDs, mono-therapy, combo-therapy, C-reactive protein, erythrocyte sedimentation rate, rheumatoid factor latex test, antinuclear antibodies, x-rays, joint aspiration, etc.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;Clinical practice guidelines from other jurisdictions for rheumatoid arthritis diagnosis, management and treatment were also reviewed (up to June 2012).&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="136" OrdBy="415" ID="408" Name="Number of Source Documents" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;Not stated&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="115" OrdBy="420" ID="409" Name="Methods Used to Assess the Quality and Strength of the Evidence" Type="picklist-choice"><FieldValue Value="Not stated" /></Field><Field FieldID="149" OrdBy="425" ID="410" Name="Rating Scheme for the Strength of the Evidence" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;Not applicable&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="116" OrdBy="430" ID="411" Name="Methods Used to Analyze the Evidence" Type="picklist-many"><FieldValue Value="Review of Published Meta-Analyses" /><FieldValue Value="Systematic Review" /></Field><Field FieldID="150" OrdBy="435" ID="412" Name="Description of the Methods Used to Analyze the Evidence" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;Not stated&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="112" OrdBy="440" ID="413" Name="Methods Used to Formulate the Recommendations" Type="picklist-choice"><FieldValue Value="Expert Consensus" /></Field><Field FieldID="145" OrdBy="445" ID="414" Name="Description of Methods Used to Formulate the Recommendations" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;This guideline is an evidence-based clinical guideline for general practitioners with consensus statements when evidence is not available. It is based on scientific evidence current as of the Effective Date.&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="146" OrdBy="450" ID="415" Name="Rating Scheme for the Strength of the Recommendations" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;Not applicable&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="148" OrdBy="460" ID="417" Name="Cost Analysis" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;A formal cost analysis was not performed and published cost analyses were not reviewed.&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="104" OrdBy="465" ID="418" Name="Method of Guideline Validation" Type="picklist-choice"><FieldValue Value="External Peer Review" /><FieldValue Value="Internal Peer Review" /></Field><Field FieldID="130" OrdBy="470" ID="419" Name="Description of Method of Guideline Validation" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;This guideline was approved by the British Columbia Medical Association, and adopted by the Medical Services Commission.&lt;/p&gt;&lt;/div&gt;" /></Field></Section><Section SecID="420" OrdBy="500" Name="Recommendations"><Field FieldID="151" OrdBy="505" ID="421" Name="Major Recommendations" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;&lt;strong&gt;&lt;span style=&quot;text-decoration: underline;&quot;&gt;Diagnosis&lt;/span&gt;&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;The approach to care of patients with rheumatoid arthritis (RA) can be considered as falling into two groups.&lt;/p&gt;&#xD;&#xA;&lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;    &lt;li&gt;Early RA (ERA) is defined as patients with symptoms of less than 3 months duration. &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Patients with established disease who have symptoms due to inflammation and/or joint damage. &lt;/li&gt;&#xD;&#xA;&lt;/ul&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;&lt;span style=&quot;text-decoration: underline;&quot;&gt;Early RA Investigation&lt;/span&gt;&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Differentiate Inflammatory from Non-inflammatory Arthritis&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;The treatment approach varies depending on whether the symptoms arise from inflammation or joint damage, making the differentiation vital.&lt;/p&gt;&#xD;&#xA;&lt;table border=&quot;1&quot; cellspacing=&quot;1&quot; cellpadding=&quot;3&quot; summary=&quot;Table: Differentiate Inflammatory from Non-inflammatory Arthritis&quot;&gt;&#xD;&#xA;    &lt;thead&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;th class=&quot;Center&quot; valign=&quot;top&quot;&gt;Feature&lt;/th&gt;&#xD;&#xA;            &lt;th class=&quot;Center&quot; valign=&quot;top&quot;&gt;Inflammatory&lt;/th&gt;&#xD;&#xA;            &lt;th class=&quot;Center&quot; valign=&quot;top&quot;&gt;Non-Inflammatory&lt;/th&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;    &lt;/thead&gt;&#xD;&#xA;    &lt;tbody&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;Joint pain&lt;/td&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;With activity and at rest&lt;/td&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;With activity&lt;/td&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;Joint swelling&lt;/td&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;Soft tissue&lt;/td&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;Bony&lt;/td&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;Local erythema&lt;/td&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;Sometimes&lt;/td&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;Absent&lt;/td&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;Local warmth&lt;/td&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;Frequent&lt;/td&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;Absent&lt;/td&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;Morning stiffness&lt;/td&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;&amp;gt;30 minutes&lt;/td&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;&amp;lt;30 minutes&lt;/td&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;Systematic symptoms&lt;/td&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;Common, especially, fatigue&lt;/td&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;Absent&lt;/td&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;    &lt;/tbody&gt;&#xD;&#xA;&lt;/table&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Differentiate RA from Other Inflammatory Arthritides&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;table border=&quot;1&quot; cellspacing=&quot;1&quot; cellpadding=&quot;3&quot; summary=&quot;Table: Differentiate RA from Other Inflammatory Arthritides&quot;&gt;&#xD;&#xA;    &lt;thead&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;th class=&quot;Center&quot; valign=&quot;top&quot;&gt;RA Likely&lt;/th&gt;&#xD;&#xA;            &lt;th class=&quot;Center&quot; valign=&quot;top&quot;&gt;Differential Diagnosis&lt;/th&gt;&#xD;&#xA;            &lt;th class=&quot;Center&quot; valign=&quot;top&quot;&gt;Features Suggesting Alternative Diagnosis&lt;/th&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;    &lt;/thead&gt;&#xD;&#xA;    &lt;tbody&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;&#xD;&#xA;            &lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;                &lt;li&gt;Morning stiffness &amp;gt;30 minutes &lt;/li&gt;&#xD;&#xA;                &lt;li&gt;Painful swelling of 3 or more joints &lt;/li&gt;&#xD;&#xA;                &lt;li&gt;Symmetric involvement of hands and feet (especially metacarpophalangeal and metatarsophalangeal joints) &lt;/li&gt;&#xD;&#xA;                &lt;li&gt;Duration of 4 or more weeks &lt;/li&gt;&#xD;&#xA;            &lt;/ul&gt;&#xD;&#xA;            &lt;/td&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;&#xD;&#xA;            &lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;                &lt;li&gt;Crystal arthropathy &lt;/li&gt;&#xD;&#xA;                &lt;li&gt;Psoriatic arthritis &lt;/li&gt;&#xD;&#xA;                &lt;li&gt;Lupus &lt;/li&gt;&#xD;&#xA;                &lt;li&gt;Reactive arthritis &lt;/li&gt;&#xD;&#xA;                &lt;li&gt;Spondyloarthropathies &lt;/li&gt;&#xD;&#xA;                &lt;li&gt;Polyarticular sepsis &lt;/li&gt;&#xD;&#xA;            &lt;/ul&gt;&#xD;&#xA;            &lt;/td&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;&#xD;&#xA;            &lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;                &lt;li&gt;Mucosal ulcers, photosensitivity, psoriasis, skin rashes &lt;/li&gt;&#xD;&#xA;                &lt;li&gt;Raynaud's &lt;/li&gt;&#xD;&#xA;                &lt;li&gt;Ocular inflammation &amp;ndash; iritis/uveitis &lt;/li&gt;&#xD;&#xA;                &lt;li&gt;Urethritis &lt;/li&gt;&#xD;&#xA;                &lt;li&gt;Inflammatory bowel disease &lt;/li&gt;&#xD;&#xA;                &lt;li&gt;Infectious diarrhea &lt;/li&gt;&#xD;&#xA;                &lt;li&gt;Nephritis &lt;/li&gt;&#xD;&#xA;                &lt;li&gt;Isolated distal interphalangeal joint inflammation &lt;/li&gt;&#xD;&#xA;            &lt;/ul&gt;&#xD;&#xA;            &lt;/td&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;    &lt;/tbody&gt;&#xD;&#xA;&lt;/table&gt;&#xD;&#xA;&lt;p&gt;&lt;em&gt;Note that extra-articular manifestations are an indication of more severe disease and thus have prognostic value.&lt;/em&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;&lt;span style=&quot;text-decoration: underline;&quot;&gt;Investigations&lt;/span&gt;&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;RA is a clinical diagnosis. Referral to a specialist should not be based on the results of lab tests if there are no clinical features suggesting RA. There are no tests that can reliably make the diagnosis of RA. If there are clinical features then the following lab tests may be useful for monitoring and ruling out other types of arthritis.&lt;/p&gt;&#xD;&#xA;&lt;table border=&quot;1&quot; cellspacing=&quot;1&quot; cellpadding=&quot;3&quot; summary=&quot;Table: Investigations into RA&quot;&gt;&#xD;&#xA;    &lt;thead&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;th class=&quot;Center&quot; valign=&quot;top&quot;&gt;Tests*&lt;/th&gt;&#xD;&#xA;            &lt;th class=&quot;Center&quot; valign=&quot;top&quot;&gt;Diagnostic Value&lt;/th&gt;&#xD;&#xA;            &lt;th class=&quot;Center&quot; valign=&quot;top&quot;&gt;Disease Activity Monitoring&lt;/th&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;    &lt;/thead&gt;&#xD;&#xA;    &lt;tbody&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;C-Reactive Protein (CRP) or Erythrocyte Sedimentation Rate (ESR)&lt;/td&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;CRP is the preferred test (BC Biomedical Laboratories Ltd., 2010; Best Practice Advocacy Centre New Zealand, 2005). Indicate only inflammatory process - very low specificity&lt;/td&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;May be useful in monitoring disease activity and response to treatment. Both can be useful, but CRP is more sensitive to short term fluctuations. ESR elevated in many but not all with active inflammation.&lt;/td&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;Rheumatoid Factor Latex Test (RF)&lt;/td&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;RF has low sensitivity and specificity for RA. Seropositive RA has a worse prognosis than seronegative RA.&lt;/td&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;No value - do not repeat&lt;/td&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;Antinuclear Antibody (ANA)&lt;/td&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;ANA is rarely positive in RA. Unless there are other clinical features indicating systemic lupus erythematosus (SLE) or other connective tissue diseases, ordering ANA is not indicated (British Columbia Guidelines and Protocols Advisory Committee, 2007).&lt;/td&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;No value - do not repeat&lt;/td&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;X-Rays&lt;/td&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;Diagnostic erosions rarely seen in disease of &amp;lt;3 months duration.&lt;/td&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;If clinically indicated, serial x-rays over years may show disease progression and indicate need for medication change.&lt;/td&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;Joint Aspiration&lt;/td&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;Joint aspiration indicated if infection or crystal arthropathy is suspected. Antibiotics may be started only after aspiration.&lt;/td&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;&amp;nbsp;&lt;/td&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;    &lt;/tbody&gt;&#xD;&#xA;&lt;/table&gt;&#xD;&#xA;&lt;p class=&quot;Note&quot;&gt;*Anti-cyclic citrullinated protein antibodies (anti-CCP) may have some value but can only be ordered by a specialist in British Columbia. If ordered by a general practitioner (GP) then the test is patient pay.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;&lt;span style=&quot;text-decoration: underline;&quot;&gt;Management&lt;/span&gt;&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Referral to Specialists&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;    &lt;li&gt;Specialist intervention has been shown to improve RA outcomes. Referrals to specialists should indicate &lt;strong&gt;&quot;Urgent: new-onset RA&quot;&lt;/strong&gt;. Copy all relevant tests to specialist. &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Referral to physiotherapist (PT) and/or occupational therapist (OT) with expertise in RA and indicate &lt;strong&gt;&quot;Urgent: new-onset RA&quot;&lt;/strong&gt;. &lt;/li&gt;&#xD;&#xA;&lt;/ul&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Management of Early RA&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;Before patient's specialist appointment initiate treatment as follows:&lt;/p&gt;&#xD;&#xA;&lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;    &lt;li&gt;Patient education: provide attached RA patient guide. &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Start nonsteroidal anti-inflammatory drugs (NSAIDs) and acetaminophen for pain management having recorded blood pressure and ordered baseline complete blood count (CBC), creatinine, electrolytes and chest x-ray. &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Can start with:&#xD;&#xA;    &lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;        &lt;li&gt;Hydroxychloroquine (O'Dell et al., 2002; O'Dell, 2004; &quot;A randomized trial,&quot; 1995) until diagnosis of RA is confirmed (see Appendix A, Non-Biologic Disease-Modifying Anti-rheumatic Drugs [DMARDs], in the original guideline document)&#xD;&#xA;        &lt;p&gt;&lt;strong&gt;OR &lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;        &lt;/li&gt;&#xD;&#xA;        &lt;li&gt;Sulfasalazine and methotrexate if confident about diagnosis and in using these medications (see Appendix A, Non-Biologic Disease-Modifying Anti-rheumatic Drugs [DMARDs], in the original guideline document). Combination DMARD therapy is the current standard of care. &lt;/li&gt;&#xD;&#xA;    &lt;/ul&gt;&#xD;&#xA;    &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;If symptoms are severe add low-dose prednisone (up to 10 mg/day). &lt;/li&gt;&#xD;&#xA;&lt;/ul&gt;&#xD;&#xA;&lt;p&gt;Consider seeing early RA patients monthly to monitor response to treatment and possible side effects of medications (Bykerk et al., 2011). Contact specialist if concerned.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;There are currently at least nine biologic medications approved for treatment of RA. They will be initiated only by specialists. As such, detailed review of this drug class is beyond the scope of this guideline. Details of initiation, dosing and monitoring are based on recommendations made by specialists in each case.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Management of Established RA&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;The objective of treatment is to suppress all inflammation and prevent joint damage. Most patients will require long-term DMARD therapy.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;Consider follow-up every 3-6 months and specialist follow-up every 6-12 months after inflammation is suppressed (Bykerk et al., 2011).&lt;/p&gt;&#xD;&#xA;&lt;p&gt;At each visit:&lt;/p&gt;&#xD;&#xA;&lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;    &lt;li&gt;Assess current drug therapy including dose and monitoring for side effects (see Appendix A, Non-Biologic Disease-Modifying Anti-rheumatic Drugs [DMARDs], in the original guideline document) &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Examine joints for active inflammation (if necessary review clinical features) &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;When baseline CRP or ESR is elevated, serial assessment may be helpful &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Review general health concerns and co-morbidities &lt;/li&gt;&#xD;&#xA;&lt;/ul&gt;&#xD;&#xA;&lt;p&gt;If the assessment suggests ongoing active inflammation, then consider or review:&lt;/p&gt;&#xD;&#xA;&lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;    &lt;li&gt;Adherence to medication regimen &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Dosage of current medications and dosages of substitutions/additions of alternative medications &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Referral back to specialist &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Referral back to PT and/or OT &lt;/li&gt;&#xD;&#xA;&lt;/ul&gt;&#xD;&#xA;&lt;p&gt;If the assessment suggests joint damage, then consider or review:&lt;/p&gt;&#xD;&#xA;&lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;    &lt;li&gt;Pain relieving modalities &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Re-referral to PT and/or OT &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Referral for surgical opinion &lt;/li&gt;&#xD;&#xA;&lt;/ul&gt;&#xD;&#xA;&lt;p&gt;Always take into account that patients may have a combination of inflammation and damage.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Consider Implications of Chronic Disease&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;Optimal outcome is achieved through a multi-disciplinary approach coordinated by the primary care physician.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;Consider or review:&lt;/p&gt;&#xD;&#xA;&lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;    &lt;li&gt;Implications of chronic pain &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Psychosocial issues &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Immunizations (flu vaccine, pneumococcal polysaccharide vaccine [PPSV]) &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Osteoporosis assessment and preventive measures. See the National Guideline Clearinghouse (NGC) summary of the Medical Services Commission, British Columbia guideline &lt;a href=&quot;/content.aspx?id=34286&quot; title=&quot;Guideline #8666&quot;&gt;Osteoporosis: Diagnosis, Treatment and Fragility Fracture Prevention&lt;/a&gt;. &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Patients with RA have an increased risk of cardiovascular disease (CVD) compared with the general population. Aggressive treatment of RA disease activity may minimize the cumulative burden of inflammation. Traditional CVD risk factors (e.g., cholesterol levels, blood pressure) should also be carefully screened and managed in this patient population. &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Encourage self-management for RA symptoms &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Smoking cessation (smoking directly aggravates RA) &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Weight management. See the Medical Services Commission, British Columbia guideline &lt;a href=&quot;http://www.bcguidelines.ca/guideline_obesity.html&quot; title=&quot;BC Ministry of Health Web site&quot;&gt;Overweight and Obese Adults: Diagnosis and Management&lt;/a&gt;. &lt;/li&gt;&#xD;&#xA;&lt;/ul&gt;&lt;/div&gt;" /></Field><Field FieldID="138" OrdBy="515" ID="423" Name="Clinical Algorithm(s)" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;None provided&lt;/p&gt;&lt;/div&gt;" /></Field></Section><Section SecID="424" OrdBy="600" Name="Evidence Supporting the Recommendations"><Field FieldID="98" OrdBy="605" ID="425" Name="References Supporting the Recommendations" Type="citation"><FieldValue Value="&lt;table&gt;&lt;tr&gt;&lt;td&gt;A randomized trial of hydroxychloroquine in early rheumatoid arthritis: the HERA  Study. Am J Med. 1995 Feb;98(2):156-68. &lt;a href=&quot;http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=7847432&quot; target=&quot;_blank&quot;&gt;PubMed&lt;/a&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;" /><FieldValue Value="&lt;table&gt;&lt;tr&gt;&lt;td&gt;BC Biomedical Laboratories Ltd. New MSP laboratory medicine funding agreement. Physicians Newsl. 2010;12:1-3.&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;" /><FieldValue Value="&lt;table&gt;&lt;tr&gt;&lt;td&gt;Best Practice Advocacy Centre New Zealand (BPAC). CRP vs ESR assessing &amp; measuring the inflammatory response. Dunedin (New Zealand): Best Practice Advocacy Centre New Zealand (BPAC); 2005 Sep. Various p. &lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;" /><FieldValue Value="&lt;table&gt;&lt;tr&gt;&lt;td&gt;British Columbia Guidelines and Protocols Advisory Committee. Antinuclear antibody (ANA) testing for connective tissue disease. Victoria (BC): British Columbia Medical Services Commission; 2007 Mar 12. &lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;" /><FieldValue Value="&lt;table&gt;&lt;tr&gt;&lt;td&gt;Bykerk VP, Akhavan P, Hazlewood GS, Schieir O, Dooley A, Haraoui B, Khraishi M, Leclercq SA, Legare J, Mosher DP, Pencharz J, Pope JE, Thomson J, Thorne C, Zummer M, Bombardier C, Canadian Rheumatology Association. Canadian Rheumatology Association recommendations for pharmacological management  of rheumatoid arthritis with traditional and biologic disease-modifying antirheumatic drugs. J Rheumatol. 2011;38:11.&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;" /><FieldValue Value="&lt;table&gt;&lt;tr&gt;&lt;td&gt;O'Dell JR, Leff R, Paulsen G, Haire C, Mallek J, Eckhoff PJ, Fernandez A, Blakely K, Wees S, Stoner J, Hadley S, Felt J, Palmer W, Waytz P, Churchill M, Klassen L, Moore G. Treatment of rheumatoid arthritis with methotrexate and hydroxychloroquine, methotrexate and sulfasalazine, or a combination of the three medications: results of a two-year, randomized, double-blind, placebo-controlled trial. Arthritis Rheum. 2002 May;46(5):1164-70. &lt;a href=&quot;http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=12115219&quot; target=&quot;_blank&quot;&gt;PubMed&lt;/a&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;" /><FieldValue Value="&lt;table&gt;&lt;tr&gt;&lt;td&gt;O'Dell JR. Therapeutic strategies for rheumatoid arthritis. N Engl J Med. 2004 Jun 17;350(25):2591-602. [121 references] &lt;a href=&quot;http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=15201416&quot; target=&quot;_blank&quot;&gt;PubMed&lt;/a&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;" /></Field><Field FieldID="139" OrdBy="610" ID="426" Name="Type of Evidence Supporting the Recommendations" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;This is an evidence-based clinical guideline for general practitioners with consensus statements when evidence was not available. The type of supporting evidence is not specifically stated for each recommendation.&lt;/p&gt;&lt;/div&gt;" /></Field></Section><Section SecID="427" OrdBy="700" Name="Benefits/Harms of Implementing the Guideline Recommendations"><Field FieldID="152" OrdBy="705" ID="428" Name="Potential Benefits" Type="text"><FieldValue Value="&lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;    &lt;li&gt;Early recognition and intervention for rheumatoid arthritis (RA) has been shown to improve outcome. &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;The use of traditional medications in combination and the new biologic therapies have revolutionised the paradigm of RA treatment in recent years. Disease modifying anti-rheumatic drugs (DMARDs), particularly when used early, change the course of the disease and are proven to reduce damage and associated disability. &lt;/li&gt;&#xD;&#xA;&lt;/ul&gt;" /></Field><Field FieldID="153" OrdBy="710" ID="429" Name="Potential Harms" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;Adverse effects of medications (see Appendix A, Non-Biologic Disease-Modifying Anti-rheumatic Drugs [DMARDs], in the original guideline document)&lt;/p&gt;&lt;/div&gt;" /></Field></Section><Section SecID="432" OrdBy="900" Name="Qualifying Statements"><Field FieldID="137" OrdBy="905" ID="433" Name="Qualifying Statements" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;The Clinical Practice Guidelines (the &quot;Guidelines&quot;) have been developed by the Guidelines and Protocols Advisory Committee on behalf of the Medical Services Commission. The Guidelines are intended to give an understanding of a clinical problem, and outline one or more preferred approaches to the investigation and management of the problem. The Guidelines are not intended as a substitute for the advice or professional judgment of a health care professional, nor are they intended to be the only approach to the management of clinical problems.&lt;/p&gt;&lt;/div&gt;" /></Field></Section><Section SecID="434" OrdBy="1000" Name="Implementation of the Guideline"><Field FieldID="131" OrdBy="1010" ID="436" Name="Description of Implementation Strategy" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;An implementation strategy was not provided.&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="117" OrdBy="1015" ID="437" Name="Implementation Tools" Type="picklist-many"><FieldValue Value="Mobile Device Resources" /><FieldValue Value="Patient Resources" /><FieldValue Value="Quick Reference Guides/Physician Guides" /><FieldValue Value="Resources" /></Field></Section><Section SecID="439" OrdBy="1100" Name="Institute of Medicine (IOM) National Healthcare Quality Report Categories"><Field FieldID="50" OrdBy="1105" ID="440" Name="IOM Care Need" Type="picklist-many"><FieldValue Value="Getting Better" /></Field><Field FieldID="51" OrdBy="1110" ID="441" Name="IOM Domain" Type="picklist-many"><FieldValue Value="Effectiveness" /><FieldValue Value="Patient-centeredness" /></Field></Section><Section SecID="442" OrdBy="1200" Name="Identifying Information and Availability"><Field FieldID="97" OrdBy="1201" ID="392" Name="Bibliographic Source(s)" Type="citation"><FieldValue Value="&lt;table&gt;&lt;tr&gt;&lt;td&gt;Medical Services Commission. Rheumatoid arthritis: diagnosis, management and monitoring. Victoria (BC): British Columbia Medical Services Commission; 2012 Sep 30. 7 p.  [12 references]&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;" /></Field><Field FieldID="124" OrdBy="1205" ID="443" Name="Adaptation" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;Not applicable: The guideline was not adapted from another source.&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="128" OrdBy="1215" ID="445" Name="Date Released" Type="text"><FieldValue Value="2012 Sep 30" /></Field><Field FieldID="158" OrdBy="1225" ID="447" Name="Guideline Developer(s)" Type="orglist-p"><FieldValue Value="Medical Services Commission, British Columbia - State/Local Government Agency [Non-U.S.]" /></Field><Field FieldID="125" OrdBy="1235" ID="449" Name="Source(s) of Funding" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;Medical Services Commission, British Columbia&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="126" OrdBy="1240" ID="450" Name="Guideline Committee" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;Guidelines and Protocols Advisory Committee&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="127" OrdBy="1245" ID="451" Name="Composition of Group That Authored the Guideline" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;Not stated&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="147" OrdBy="1250" ID="452" Name="Financial Disclosures/Conflicts of Interest" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;Not stated&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="120" OrdBy="1256" ID="393" Name="Guideline Status" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;This is the current release of the guideline.&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="118" OrdBy="1260" ID="454" Name="Guideline Availability" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;Electronic copies: Available from the &lt;a href=&quot;http://www.bcguidelines.ca/guideline_ra.html&quot; title=&quot;British Columbia Ministry of Health Web site&quot;&gt;British Columbia Ministry of Health Web site&lt;/a&gt;.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;The guideline is also available for mobile devices from the &lt;a href=&quot;http://clinipearls.ca/bcguidelines/&quot; title=&quot;British Columbia Ministry of Health Web site&quot;&gt;British Columbia Ministry of Health Web site&lt;/a&gt;.&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="119" OrdBy="1265" ID="455" Name="Availability of Companion Documents" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;The following is available:&lt;/p&gt;&#xD;&#xA;&lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;    &lt;li&gt;Rheumatoid arthritis: diagnosis, management and monitoring summary. Victoria (BC): British Columbia Medical Services Commission; 2012 Sep 1. 2 p. Electronic copies: Available in Portable Document Format (PDF) from the &lt;a href=&quot;http://www.bcguidelines.ca/pdf/ra_guideline_summary.pdf&quot; title=&quot;British Columbia Ministry of Health Web site&quot;&gt;British Columbia Ministry of Health Web site&lt;/a&gt;. &lt;/li&gt;&#xD;&#xA;&lt;/ul&gt;&#xD;&#xA;&lt;p&gt;In addition, Appendix A in the &lt;a href=&quot;http://www.bcguidelines.ca/guideline_ra.html&quot; title=&quot;British Columbia Ministry of Health Web site&quot;&gt;original guideline document&lt;/a&gt; contains more information on non-biologic disease-modifying anti-rheumatic drugs (DMARDs).&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="143" OrdBy="1275" ID="457" Name="Patient Resources" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;The following is available:&lt;/p&gt;&#xD;&#xA;&lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;    &lt;li&gt;Rheumatoid arthritis: a guide for adult patients. Victoria (BC): British Columbia Medical Services Commission; 2012 Sep. 2 p. Electronic copies: Available in Portable Document Format (PDF) from the &lt;a href=&quot;http://www.bcguidelines.ca/pdf/rheumatoid_arthritis_pg.pdf&quot; title=&quot;British Columbia Ministry of Health Web site&quot;&gt;British Columbia Ministry of Health Web site&lt;/a&gt;. &lt;/li&gt;&#xD;&#xA;&lt;/ul&gt;&#xD;&#xA;&lt;p class=&quot;Disclaimer&quot;&gt;Please note: This patient information is intended to provide health professionals with information to share with their patients to help them better understand their health and their diagnosed disorders. By providing access to this patient information, it is not the intention of NGC to provide specific medical advice for particular patients. Rather we urge patients and their representatives to review this material and then to consult with a licensed health professional for evaluation of treatment options suitable for them as well as for diagnosis and answers to their personal medical questions. This patient information has been derived and prepared from a guideline for health care professionals included on NGC by the authors or publishers of that original guideline. The patient information is not reviewed by NGC to establish whether or not it accurately reflects the original guideline's content.&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="142" OrdBy="1280" ID="458" Name="NGC Status" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;This NGC summary was completed by ECRI Institute on February 12, 2013. The information was verified by the guideline developer on March 20, 2013. This summary was updated by ECRI Institute on October 28, 2013 following the U.S. Food and Drug Administration advisory on Acetaminophen. This summary was updated by ECRI Institute on September 18, 2015 following the U.S. Food and Drug Administration advisory on non-aspirin nonsteroidal anti-inflammatory drugs (NSAIDs).&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="141" OrdBy="1290" ID="460" Name="Copyright Statement" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;This NGC summary is based on the original guideline, which is subject to the guideline developer's copyright restrictions.&lt;/p&gt;&lt;/div&gt;" /></Field></Section><Section SecID="99999" OrdBy="99999" Name="Disclaimer"><Field FieldID="99999" OrdBy="99999" ID="99999" Name="NGC Disclaimer" Type="text"><FieldValue Value="&lt;p&gt;The National Guideline Clearinghouse™ (NGC) does not develop, produce, approve, or endorse the guidelines represented on this site.&lt;/p&gt; &#xD;&#xA;&lt;p&gt;All guidelines summarized by NGC and hosted on our site are produced under the auspices of medical specialty societies, relevant professional associations, public or private organizations, other government agencies, health care organizations or plans, and similar entities.&lt;/p&gt; &#xD;&#xA;&lt;p&gt;Guidelines represented on the NGC Web site are submitted by guideline developers, and are screened solely to determine that they meet the NGC Inclusion Criteria which may be found at &lt;a href=&quot;/about/inclusion-criteria.aspx&quot;&gt;http://www.guideline.gov/about/inclusion-criteria.aspx&lt;/a&gt;.&lt;/p&gt; &#xD;&#xA;&lt;p&gt;NGC, AHRQ, and its contractor ECRI Institute make no warranties concerning the content or clinical efficacy or effectiveness of the clinical practice guidelines and related materials represented on this site. Moreover, the views and opinions of developers or authors of guidelines represented on this site do not necessarily state or reflect those of NGC, AHRQ, or its contractor ECRI Institute, and inclusion or hosting of guidelines in NGC may not be used for advertising or commercial endorsement purposes.&lt;/p&gt; &#xD;&#xA;&lt;p&gt;Readers with questions regarding guideline content are directed to contact the guideline developer.&lt;/p&gt;" /></Field></Section></Version>
